The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2

Journal of Clinical Oncology

Volumn 20, Issue 9, 2002, Pages 2310-2318

  Lakhani, Sunil R ^a   Van De Vijver, Marc J ^a   Jacquemier, Jocelyne ^a   Anderson, Thomas J ^a   Osin, Peter P ^a   McGuffog, Lesley ^a   Easton, Douglas F ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC VALUE; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; LOGISTIC MODELS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036569877     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.09.023     Document Type: Article

References (42)

1. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases - Breast Cancer Linkage Consortium
2. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
3. Inherited BRCA2 mutation associated with high grade breast cancer
4. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study
5. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer
6. Tumour biological features of BRCA1-induced breast and ovarian cancer
7. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
8. Pathobiologic characteristics of hereditary breast cancer
9. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
10. BRCA2 hereditary breast cancer pathophenotype
11. BRCA-associated breast cancer in young women
12. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
13. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: Findings from a focus group and a needs-assessment survey
14. The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2
15. The behaviour of maximum likelihood estimates under nonstandard conditions
16. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study
17. Gene-expression profiles in hereditary breast cancer
18. Profiling familial breast cancer
19. Steroid hormone receptors in breast cancer management
20. The relationship between prognostic and predictive factors in the management of breast cancer
21. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers
22. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers
23. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study
24. Dissociation between steroid receptor expression and cell proliferation in the human breast
25. DNA ploidy and pS2 protein expression in breast cancer
26. p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding
27. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications
28. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer
29. Prognostic and predictive value of p53 and p21 in breast cancer
30. Pathological prognostic factors in breast cancer
31. p53 mutations in BRCA1-associated familial breast cancer
32. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
33. BRCA1-p53 relationship in hereditary breast cancer
34. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution
35. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions
36. Role of BRCA gene dysfunction in breast and ovarian cancer predisposition
37. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation
38. Developmental studies of Brcal and Brca2 knock-out mice
39. Risks of cancer in BRCA/-mutation carriers: Breast Cancer Linkage Consortium
40. Novel indications for BRCA1 screening using individual clinical and morphological features
41. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer
42. Pathologyical features and BRCA1 mutation screening in premenopausal breast cancer patients